We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Intec Pharma Ltd.  (“Intec” or the “Company”) (NASDAQ: NTEC) in connection with the proposed acquisition of the Company by Decoy Biosystems, Inc.(“Decoy”).  Upon consummation of the transaction, the Company’s shareholders will own approximately 25% of the combined entity, with Decoy shareholders owning approximately 75%.

WeissLaw LLP is investigating whether Intec’s board acted in the best interest of Intec’s public shareholders in agreeing to the proposed transaction, whether the board was fully informed as to the valuation of Decoy, and whether all information regarding the process undertaken by the board and the valuation of the transaction will be fully and fairly disclosed to Intec’s public shareholders.

WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties.  We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases.  If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at stockinfo@weisslawllp.com

‍